A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 MG/DAY) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures

Grants and Contracts Details

StatusFinished
Effective start/end date3/1/06 → 11/30/08

Funding

  • Quintiles Inc: $70,243.00